COG AALL0232 PROTOKOLÜ

Kaynaklar:

1- Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children’s Oncology Group study AALL0232. Blood. 2015;126:964–971

2- Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-2388.

3-Aplenc, R., B. T. Fisher, Y. S. Huang, Y. Li, T. A. Alonzo, R. B. Gerbing, et al. 2012. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children’s Oncology Group. Pharmacoepidemiol. Drug Saf. 21(Suppl 2):37–43.